Point72 (DIFC)’s ADMA Biologics ADMA Stock Holding History

Point72 (DIFC)’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,298	Closed	-$22.3K	–	1625
2024 Q4	$22.3K	Buy	+1,298	New	+$24.4K	﹤0.01%	1246

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Perpetual Ltd Sydney, New South Wales, Australia $7B AUM 19.75% 1-Year Est. Return

Point72 (DIFC)'s ADMA Position: Q1 2025 in Review

Point72 (DIFC) sold out of ADMA Biologics (ADMA) in Q1 2025, closing a stake of 1,298 shares — an estimated $22.3K sold.

Point72 (DIFC) first reported a position in ADMA in Q4 2024 and held it in 1 quarter. The position peaked at $22.3K in Q4 2024. 347 funds tracked by Wall St. Rank hold ADMA as of Q1 2025.

Point72 (DIFC) reported no remaining ADMA Biologics position as of Q1 2025 after selling out during the quarter.
Point72 (DIFC) sold 1,298 ADMA Biologics shares in Q1 2025, an estimated $22.3K.
Point72 (DIFC) first reported a position in ADMA Biologics in Q4 2024 and held it in 1 quarter.
Point72 (DIFC)'s ADMA Biologics position peaked at $22.3K in Q4 2024.
347 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2025.

Based on Point72 (DIFC)'s 13F filing for Q1 2025, filed 15 May 2025.